338 289

Cited 0 times in

고지혈증 치료 가이드라인

Other Titles
 Lipid-Lowering Therapy Guidelines 
Authors
 이상학 
Citation
 Korean Journal of Medicine, Vol.94(5) : 396-402, 2019 
Journal Title
 Korean Journal of Medicine 
ISSN
 1226-329X 
Issue Date
2019
Keywords
Cholesterol ; Atherosclerosis ; Therapeutics ; Lipoproteins
Abstract
The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit” is the main idea underlying all guidelines, there are some differences in the details among them. The US guidelines recommend pharmacological LLT based on a patient’s risk category, independently of their low-density lipoprotein-cholesterol (LDL-C) level. However, the European and Korean guidelines consider the patient’s risk category and LDL-C at the same time. Lifestyle modifications are suggested in parallel in all guidelines. The newest US guidelines have characteristically revived target LDL-C values in some patient groups and indications for non-statin drugs (ezetimibe and PCSK9 inhibitors), whereas the European and Korean guidelines have maintained target LDL-C values as usual. It is universally accepted that statins are the first-line agent. Adding ezetimibe, bile acid sequestrants, or PCSK9 inhibitors is recommended as a second line treatment. Appreciating the trend and background of the newest LLT guidelines will be essential to maximize cardiovascular prevention in patients.
Files in This Item:
T201903815.pdf Download
DOI
10.3904/kjm.2019.94.5.396
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Sang Hak(이상학) ORCID logo https://orcid.org/0000-0002-4535-3745
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/173051
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links